Korman, N.; Papp, K.; Bagel, J. .; Foley, P.; Morita, A.; Banerjee, S.; Colston, E.; Wang, T.; Throup, J.; Thaci, D. Deucravacitinib, an Oral, Selective Tyrosine Kinase 2 (TYK2) Inhibitor, Versus Placebo and Apremilast in Moderate to Severe Plaque Psoriasis: Onset of Action in the Phase 3 POETYK PSO-1 and POETYK PSO-2 Trials. J of Skin 2021, 5, s39.